Rationale for Phase III PROSPECT Trial in Prostate Cancer
Nicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.
Nicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.
The idea was to stimulate the immune system with a vaccine containing 3 pieces of the prostate cancer. When patients relapse after 1 to 3 years with prostate cancer, the prostate-specific antigen (PSA) often increases, Vogelzang explains. Researchers hypothesized that if you could stimulate the immune system with the virus by a bystander effect, it would work.
